Continuing its efforts to address high prescription drug costs, insurer Highmark entered into a new outcomes-based contract with Boehringer Ingelheim for Jardiance (empagliflozin), an oral medicine indicated to lower blood sugar in adults with type 2 diabetes, and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Sales of some of Novo Nordisk’s key drugs in second-quarter 2018 fell short of expectations and the drugmaker said prices in the key U.S. market would be lower in 2019.
Paris-based Sanofi reported a decrease in second-quarter 2018 net sales of 5.7 percent, down to 8.176 billion euros.
Research published in the journal Nature by researchers at the National Health Research Institutes in Taiwan and the National Institute on Aging, National Institutes of Health in the U.S. suggest that a class of diabetes medications known as GLP-1 analogs may be effective treatments for Parkinson’s disease.
Eli Lilly and Co. will take the company’s Elanco animal health business public and posted better-than-expected quarterly profit, helped by demand for the diabetes drugs Trulicity and Humalog.
Janssen Pharmaceuticals halted the company’s Phase III chronic kidney disease trial for Invokana early due to the fact that the SGLT2 diabetes drug had already achieved pre-specified efficacy data.
J&J topped analysts’ estimates for Q2 2018 profit and revenue with strong demand for the cancer drugs Zytiga and Darzalex.
Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed the Swiss drugmaker’s new medicine reduced symptoms in people at high risk of complications.
Sanofi sees a more diversified pipeline driving a return to growth at the company’s diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance.
Women who develop high blood pressure during pregnancy may be more likely to experience it again later or be diagnosed with other risk factors for heart disease like high cholesterol or diabetes, a U.S. study suggests.